MedTrace Logo

Application of Thrombin Gel Matrix for the Prevention of Lymphocele in Patients With Endometrial Cancer.

NCT04205864 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 72

Last updated 2020-07-07

No results posted yet for this study

Summary

To compare the incidence of lymphocele in Endometrial cancer patients with thrombin gel matrix used and not used during pelvic lymph node dissection.

Conditions

  • Lymphocele
  • Lymphocele After Surgical Procedure
  • Endometrium Cancer

Interventions

DRUG

Thrombi-Gel

Thrombin gel Matrix applied on pelvic lymphadenectomy areas after lympadenectomy

PROCEDURE

Conventional Pelvic lymphadenectomy

Conventional Pelvic lymphadenectomy

Sponsors & Collaborators

  • Kocaeli University

    lead OTHER

Principal Investigators

  • Şener Gezer, M.D · Kocaeli University

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-12-20
Primary Completion
2020-07-01
Completion
2020-07-02

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04205864 on ClinicalTrials.gov